News Home

Is Revance Therapeutics Inc (RVNC) a Good Choice in Biotechnology Friday?

Friday, March 31, 2023 04:01 PM | InvestorsObserver Analysts

Mentioned in this article

Is Revance Therapeutics Inc (RVNC) a Good Choice in Biotechnology Friday?

The 67 rating InvestorsObserver gives to Revance Therapeutics Inc (RVNC) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, RVNC’s 67 overall rating means the stock scores better than 67 percent of all stocks.

Overall Score - 67
RVNC has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on RVNC!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Revance Therapeutics Inc Stock Today?

Revance Therapeutics Inc (RVNC) stock is trading at $31.95 as of 3:45 PM on Friday, Mar 31, a gain of $0.82, or 2.63% from the previous closing price of $31.13. The stock has traded between $31.12 and $32.39 so far today. Volume today is below average. So far 935,463 shares have traded compared to average volume of 1,322,299 shares. Click Here to get the full Stock Report for Revance Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App